Treatment of idiopathic thrombocytopenic purpura with ascorbate

Alan Brox, Kang Howson‐Jan, Axel A. Fauser
In: British Journal of Haematology · 1988 · vol. 70(3) , pp. 341–344 · doi:10.1111/j.1365-2141.1988.tb02492.x · PMID:3207627 · W2027646686
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher

Abstract

The treatment of idiopathic thrombocytopenic purpura (ITP) includes corticosteroids, danazol, splenectomy and various immunosuppressives. Treatment can be difficult for those patients refractory to these modalities and/or those patients intolerant of the secondary effects. In this paper we report on the use of ascorbate in the treatment of ITP and its successful use in seven of 11 patients studied. We found that therapy with ascorbate appeared to improve the platelet count and the intravascular survival of platelets. Because of excellent patient compliance and its lack of toxicity, it may be an alternative for the treatment of ITP. The exact role of ascorbate in the treatment of ITP, as well as its mechanism of action, await further study.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (17)

Source provenance

openalex
last seen: 2026-05-11T05:50:48.314143+00:00
unpaywall
last seen: 2026-08-24T06:27:14.670421+00:00
License: CC0 · commercial use OK